文献速递胃肠外科围术期管理与 ERAS

预防性糖皮质激素对食管癌切除术后院内死亡与呼吸衰竭的影响:日本全国住院数据研究

Impact of Prophylactic Corticosteroid Use on In-hospital Mortality and Respiratory Failure After Esophagectomy for Esophageal Cancer: Nationwide Inpatient Data Study in Japan.
PubMed 文献 · Ann Surg · 2022-07-14

该研究基于日本全国住院数据库,纳入2010年7月至2019年3月间接受肿瘤性食管切除术的35501例患者,其中22620例(63.7%)预防性使用糖皮质激素。经稳定逆概率治疗加权等分析,预防性糖皮质激素使用与院内死亡、呼吸衰竭及严重呼吸衰竭风险降低显著相关,且未增加吻合口漏比例。

要点

  • 预防性糖皮质激素与食管切除术后院内死亡风险降低相关(OR=0.80)。
  • 预防性糖皮质激素与呼吸衰竭(OR=0.84)及严重呼吸衰竭(OR=0.87)风险降低相关。
  • 预防性糖皮质激素未增加吻合口漏比例,并可能缩短术后住院时间、降低总住院费用。

核心结论

  • 肿瘤性食管切除术中预防性使用糖皮质激素与较低的院内死亡率、呼吸衰竭及严重呼吸衰竭风险相关,提示术前糖皮质激素使用可能有益。

研究设计与样本

  • 基于日本全国住院数据库的回顾性队列研究,纳入2010年7月至2019年3月接受肿瘤性食管切除术的35501例患者。
  • 采用稳定逆概率治疗加权、倾向性评分匹配及工具变量分析调整混杂因素。

主要发现

  • 22620例(63.7%)患者预防性使用糖皮质激素。
  • 院内死亡、呼吸衰竭、严重呼吸衰竭分别发生924例(2.6%)、5440例(15.3%)、2861例(8.1%)。
  • 稳定逆概率加权分析显示糖皮质激素与院内死亡风险降低相关(OR=0.80;95%CI:0.69-0.93)。
  • 糖皮质激素与呼吸衰竭风险降低相关(OR=0.84;95%CI:0.79-0.90),与严重呼吸衰竭风险降低相关(OR=0.87;95%CI:0.80-0.95)。
  • 糖皮质激素与术后住院时间缩短及总住院费用降低相关;倾向性评分匹配显示吻合口漏比例无差异,工具变量分析结果相似。

临床怎么用

  • 在肿瘤性食管切除术围术期,可考虑预防性使用糖皮质激素以降低院内死亡及呼吸衰竭风险,但需结合患者个体情况权衡。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To assess the effect of preoperative prophylactic corticosteroid use on short-term outcomes after oncologic esophagectomy. BACKGROUND: Previous studies have shown that prophylactic corticosteroid use may decrease the risk of respiratory failure following esophagectomy by attenuating the perioperative systemic inflammation response. However, its effectiveness has been controversial, and its impact on mortality remains unknown. METHODS: Data of patients who underwent oncologic esophagectomy between July 2010 and March 2019 were extracted from a Japanese nationwide inpatient database. Stabilized inverse probability of treatment weighting, propensity score matching, and instrumental variable analyses were performed to investigate the associations between prophylactic corticosteroid use and short-term outcomes, such as in-hospital mortality and respiratory failure, adjusting for potential confounders. RESULTS: Among 35,501 eligible patients, prophylactic corticosteroids were used in 22,620 (63.7%) patients. In-hospital mortality, respiratory failure, and severe respiratory failure occurred in 924 (2.6%), 5440 (15.3%), and 2861 (8.1%) patients, respectively. In stabilized inverse probability of treatment weighting analyses, corticosteroids were significantly associated with decreased in-hospital mortality [odds ratio (OR)=0.80; 95% confidence interval (CI): 0.69-0.93], respiratory failure (OR=0.84; 95% CI: 0.79-0.90), and severe respiratory failure (OR=0.87; 95% CI: 0.80-0.95). Corticosteroids were also associated with decreased postoperative length of stay and total hospitalization costs. The proportion of anastomotic leakage did not differ with the use of Propensity score matching and instrumental variable analysis demonstrated similar results. CONCLUSIONS: Prophylactic corticosteroid use in oncologic esophagectomy was associated with lower in-hospital mortality as well as decreased respiratory failure and severe respiratory failure, suggesting a potential benefit for preoperative corticosteroid use in esophagectomy.

来源:Ann Surg,查看原文。版权归原作者所有。

引用

  1. Hirano Y, Konishi T, Kaneko H, et al. Impact of Prophylactic Corticosteroid Use on In-hospital Mortality and Respiratory Failure After Esophagectomy for Esophageal Cancer: Nationwide Inpatient Data Study in Japan. Ann Surg. 2022. PMID: 35833418. doi:10.1097/SLA.0000000000005502

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。